| HIV Infections
Cabenuva vs Prezcobix
Side-by-side clinical, coverage, and cost comparison for hiv infections.Deep comparison between: Cabenuva vs Prezcobix with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPrezcobix has a higher rate of injection site reactions vs Cabenuva based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Prezcobix but not Cabenuva, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cabenuva
Prezcobix
At A Glance
IM injection (gluteal)
Every 4 weeks or every 8 weeks
INSTI + NNRTI combination
Oral
Once daily
HIV-1 protease inhibitor
Indications
- HIV Infections
- HIV Infections
Dosing
HIV Infections (Monthly Dosing) Initiation: cabotegravir 600 mg IM + rilpivirine 900 mg IM on last day of current antiretroviral therapy or oral lead-in; Continuation: cabotegravir 400 mg IM + rilpivirine 600 mg IM every month thereafter. Separate gluteal injection sites required.
HIV Infections (Every 2-Month Dosing) Initiation: cabotegravir 600 mg IM + rilpivirine 900 mg IM on last day of current antiretroviral therapy or oral lead-in, repeated 1 month later; Continuation: cabotegravir 600 mg IM + rilpivirine 900 mg IM every 2 months thereafter. Separate gluteal injection sites required.
HIV Infections Adults and pediatric patients >=40 kg: 800 mg/150 mg once daily with food; pediatric patients 25 kg to <40 kg: 675 mg/150 mg once daily with food; pediatric patients 3 years and older, 15 kg to <25 kg: 600 mg/90 mg tablet for oral suspension dispersed in water, once daily with food.
Contraindications
- Previous hypersensitivity reaction to cabotegravir or rilpivirine
- Carbamazepine, oxcarbazepine, phenobarbital, phenytoin (anticonvulsants)
- Rifabutin, rifampin, rifapentine (antimycobacterials)
- Dexamethasone (systemic, more than single dose)
- St. John's wort (Hypericum perforatum)
- Co-administration with alfuzosin
- Co-administration with carbamazepine, phenobarbital, or phenytoin
- Co-administration with colchicine in patients with renal and/or hepatic impairment
- Co-administration with rifampin
- Co-administration with lurasidone
- Co-administration with pimozide
- Co-administration with dronedarone
- Co-administration with ivabradine
- Co-administration with ranolazine
- Co-administration with ergot derivatives (dihydroergotamine, ergotamine, methylergonovine)
- Co-administration with St. John's wort (Hypericum perforatum)
- Co-administration with elbasvir/grazoprevir
- Co-administration with lomitapide
- Co-administration with lovastatin or simvastatin
- Co-administration with naloxegol
- Co-administration with sildenafil when used for pulmonary arterial hypertension
- Co-administration with orally administered midazolam or triazolam
Adverse Reactions
Most common (>=2%) Injection site reactions (pain/discomfort, nodules, induration, swelling, erythema, pruritus, bruising/discoloration, warmth, hematoma), pyrexia, fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness, rash
Serious Hypersensitivity reactions including angioedema and urticaria, hepatotoxicity, depression and suicidal ideation/attempt, severe skin reactions including DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis
Postmarketing Hypersensitivity reactions, nephrotic syndrome, severe skin and hypersensitivity reactions including DRESS, Stevens-Johnson syndrome, toxic epidermal necrolysis
Most common (>=5%) Diarrhea, nausea, rash, headache, abdominal pain, vomiting
Postmarketing Redistribution of body fat, rhabdomyolysis (with HMG-CoA reductase inhibitors), crystal nephropathy, crystalluria, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug rash with eosinophilia and systemic symptoms
Pharmacology
Cabotegravir inhibits HIV integrase by binding to the active site and blocking the strand transfer step essential for HIV replication. Rilpivirine is an NNRTI that inhibits HIV-1 replication by non-competitive inhibition of HIV-1 reverse transcriptase.
Darunavir is an HIV-1 protease inhibitor that selectively inhibits cleavage of HIV-1 Gag-Pol polyproteins in infected cells, preventing formation of mature virus particles; cobicistat is a mechanism-based CYP3A inhibitor that increases darunavir systemic exposure without intrinsic antiviral activity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cabenuva
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (0/12)
Prezcobix
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (1/12) · Qty limit (11/12)
UnitedHealthcare
Cabenuva
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Prezcobix
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Cabenuva
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Prezcobix
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Cabenuva Patient Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CabenuvaView full Cabenuva profile
PrezcobixView full Prezcobix profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.